Questionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal

Similar documents
Questionnaire. Apotex-Inc. v Sanofi-Aventis

Selection Inventions the Inventive Step Requirement, other Patentability Criteria and Scope of Protection

Jordanian Patent Office

FINLAND Patents Act No. 550 of December 15, 1967 as last amended by Act No. 101/2013 of January 31, 2013 Enter into force on 1 September 2013

Issues of Patent Drafting in Canadian Patent Law: A Unique Paradigm. By Livia Aumand & John Norman. Gowling WLG (Canada) LLP

Answer of the Canadian National Group

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

SWEDEN PATENTS ACT No.837 of 1967 in the version in force from July 1, 2014

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

Second medical use or indication claims. [Please insert name last name in CAPITAL letters please]

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

Second medical use or indication claims. Winnie Tham, Edmund Kok, Nicholas Ong

HUNGARY Patent Act Act XXXIII of 1995 as consolidated on March 01, 2015

Intellectual Property Laws Amendment Bill 2013 No., 2013

CANADA: INTERNATIONAL TREATIES AND THE PROMISE OF THE PATENT

The Patent Examination Manual. Section 10: Meaning of useful. Meaning of useful. No clear statement of utility. Specific utility

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

From Law of Patents, Layout Designs of Integrated Circuits, Plant Varieties, and Industrial Designs, Chapter Two:

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

Working Guidelines Q217. The patentability criteria for inventive step / non-obviousness

PATENT ACT (UNOFFICIAL CLEAR TEXT) I. GENERAL PROVISIONS

Second medical use or indication claims. Mr. Antonio Ray ORTIGUERA Angara Abello Concepcion Regala & Cruz Law Offices Philippines

Patentability what will a Patent Office allow? Darren Smyth 29 January 2010

Patentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

The use of prosecution history in post-grant patent proceedings. Maria CRUZ GARCIA, Isabel FRANCO, João JORGE, Teresa SILVA GARCIA

INVENTION DISCLOSURE FORM

Intellectual Property Laws Amendment Act 2015

11th Annual Patent Law Institute

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

The methods and procedures described must be directly applicable to production.

Prosecuting an Israel Patent Application and Beyond

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

CA/PL 7/99 Orig.: German Munich, SUBJECT: Revision of the EPC: Articles 52(4) and 54(5) President of the European Patent Office

of 25 June 1954 (Status as of 1 January 2017) para. 2) is not patentable as an invention. 7

The use of prosecution history in post-grant patent proceedings. The Groups are invited to answer the following questions under their national laws.

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

Second medical use or indication claims

When Is An Invention. Nevertheless Nonobvious?

Groups are invited to answer the following questions under their national laws:

Claims and Determining Scope of Protection

Construction of second medical use claims. The Hon. Mr Justice Richard Arnold

An introduction to European intellectual property rights

Global Access to Medicines Program Compiled by Stephanie Rosenberg. December 2, This chart compares provisions from the following texts:

Intellectual Property Department Hong Kong, China. Contents

ExCo Berlin, Germany

THE PATENT LAW 1. GENERAL PROVISIONS. Article 1. This Law shall regulate the legal protection of inventions by means of patents.

Switzerland. Esther Baumgartner Christoph Berchtold Simon Holzer Kilian Schärli Meyerlustenberger Lachenal. 1. Small molecules

In the Arbitration under Chapter 11 of the North American Free Trade Agreement and the UNCITRAL Arbitration Rules. Eli Lilly and Company.

Title: The patentability criterion of inventive step / non-obviousness

Suzannah K. Sundby. canady + lortz LLP. David Read. Differences between US and EU Patent Laws that Could Cost You and Your Startup.

POTENTIAL PATENT APPLICATION QUESTIONNAIRE

Second medical use or indication claims

Part 1 Applications for Patents for Inventions

ELI LILLY AND COMPANY. Disputing Investor, -and- THE GOVERNMENT OF CANADA. Disputing Party

Law on the protection of inventions No. 50/2008 of the Republic of Moldova can be found at:

Second medical use or indication claims

PATENT LAW OF GEORGIA CHAPTER I. GENERAL PROVISIONS

Courtesy translation provided by WIPO, 2012

SUPREME COURT OF CANADA. APPEAL HEARD: November 8, 2016 JUDGMENT RENDERED: June 30, 2017 DOCKET: 36654

COMPARATIVE STUDY REPORT REQUIREMENTS FOR DISCLOSURE AND CLAIMS - 1 -

DRAFT PATENT LAW OF GEORGIA CHAPTER I. GENERAL PROVISIONS

India Patent Act, 2003 Updated till March 11th, 2015

[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights

Examination Practice Respecting Purposive Construction PN

Foreign Filing Procedures

How patents work An introduction for law students

Section 1: General. This question does not imply that the topic of exclusions from patentability is dealt with in this question exhaustively.

IN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976)

Inventive Step and Non-obviousness: Global Perspectives

Guidelines for completing a Knowledge Development Box (KDB) Certificate Application

AIPPI Study Question - Patentability of computer implemented inventions

Questionnaire May 2002 Q163 Attorney-Client Privilege and the Patent and/or Trademark Attorneys Profession. Answer of the Brazilian Group

Pharma Session 1: Sufficiently plausible?

GENEVA STANDING COMMITTEE ON THE LAW OF PATENTS. Thirteenth Session Geneva, March 23 to 27, 2009

SWITZERLAND Patent Law as last amended on March 20, 2009 ENTRY INTO FORCE: January 1, 2012

LATVIA Patent Law adopted on 15 February 2007, with the changes of December 15, 2011

The Consolidate Patents Act

Question Q204P. Liability for contributory infringement of IPRs certain aspects of patent infringement

COMMENTARY. Antidote to Toxic Divisionals European Patent Office Rules on Partial Priorities. Summary of the Enlarged Board of Appeal s Decision

pct2ep.com Guide to claim amendment after EPO regional phase entry

THE ACTS ON AMENDMENTS TO THE PATENT ACT */**/***/****/*****/******/*******

Working Guidelines Q238. Second medical use and other second indication claims

Note: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail.

MATERIAL TRANSFER AGREEMENT

United Kingdom. By Penny Gilbert, Kit Carter and Stuart Knight, Powell Gilbert LLP

Patent Litigation in Taiwan: overview

AIPPI Study Question - Patentability of computer implemented inventions

The Patents Act 1977 (as amended)

HUNGARIAN INTELLECTUAL PROPERTY OFFICE (HIPO)

Advisory Council on Intellectual Property

Patent Act) I. Outline of the Case The plaintiff filed a request to the Japan Patent Office (JPO) for a trial for invalidation of Patent No e

FINAL REPORT THE PATENTS AND DESIGNS ACT, INTRODUCTION PATENTS

Additional Features of New Patent Ordinance

The person skilled in the art in the context of the inventive step requirement in patent law. Prefatory Statement

Questionnaire on Exceptions and Limitations to Patent Rights

Compilation date: 24 February Includes amendments up to: Act No. 61, Registered: 27 February 2017

2011 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

Q233 Grace Period for Patents

Transcription:

National Group: Hungarian Title: Reporter: Contributors: Questionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal Dr. PETHŐ, Árpád Dr. PETHŐ, Árpád, MOLNÁR, Imre, Dr. TÁLAS, József Date: June 5, 2014 Questions A. Utility or industrial applicability requirement 1. Does your national law have a utility or industrial applicability requirement for patentability? [Please just answer 'yes' or 'no. If 'no', you do not need to answer the remaining questions.] 2. Please briefly describe the utility or industrial applicability requirement, including whether it is based on: both. The industrial applicability requirement is based both on statute and jurisprudence in our country. According to the Hungarian Patent Act, industrial applicability is a major prerequisite of patentability. Article 1 says: (1) Patents shall be granted for any inventions in any field of technology that are new, involve an inventive step and are susceptible of industrial application. Article 5(1) of the Patent Act reads as follows: "(1) An invention shall be considered susceptible of industrial application if it can be made or used in any sector of industry or agriculture." Paragraph 5 of Chapter III of the Manual of Patent Examination (available only in the Hungarian language), issued by the Hungarian Intellectual Property Office (in the following: HIPO), deals in detail with industrial applicability in the following subparagraphs: 1

5.1 Definition of industrial applicability 5.2. Judgment on industrial applicability 5.2.1. Definition of "industry" 5.2.2. Definition of "applicability" 5.3 Judgment on medical, surgical and diagnostic methods This latter subparagraph provides guidance in the respect what is considered to be an industrial application by the HIPO. In this respect it is worth to refer to the repealed (in 2007) Article 5(2) of the Patents Act which reads as follows: "(2) In particular, the therapeutic or surgical procedures for the treatment of the human body or animals, as well as diagnostic procedures to be carried out on the human body or animals shall not be deemed susceptible of industrial application. However, this provision shall not apply to any product used in such procedures, in particular to any material (compound) and mixture." 3. What must be disclosed in the patent specification to satisfy the utility or industrial applicability requirement? In particular, must the patent specification disclose: (a) the utility or industrial applicability; (b) a basis (eg test data) to prove or demonstrate that the utility or industrial applicability is achieved; and/or a basis (eg test data) and/or a line of reasoning from which the utility or industrial applicability may be predicted? 2

Although it is up to the HIPO and/or the relevant courts to decide whether industrial applicability is satisfactorily disclosed in a patent application and/or patent, the practice and the jurisprudence mostly requires the satisfaction of condition as defined above. Our court practice demonstrates that the reasoned predictability of industrial applicability may effectively be questioned if the invention is doubtful to fulfill its declared goal as disclosed originally in the description. 4. Is the basis for any disclosure required in the patent specification: both? B. Prosecution 5. Is it necessary to demonstrate utility or industrial applicability during prosecution? [Please just answer 'yes' or 'no'. If 'no', you do not need to answer questions 6-8 but please answer question 9.] 6. Is the requirement to demonstrate utility or industrial application during prosecution based on: (a) statute both? 7. Is there a material date by which the utility or industrial applicability be demonstrated? It is worth to cite Article 60(1) of the Patent Act in this respect: "A patent application shall disclose the invention in a manner sufficiently clear and detailed for it to be carried out by a person skilled in the art on the basis of the description and the drawings. The industrial applicability of a sequence or a partial sequence of a gene shall be disclosed in the patent application." Apart from the last sentence of this Article it is necessary, in our view, at least to define clearly the industrial applicability of the invention in the original patent application as filed. 8. What evidence is required to demonstrate utility or industrial applicability? For example: (a) can post filing evidence be used; and/or (b) can the applicant rely upon the utility or industrial applicability being soundly predicted as opposed to demonstrated? 3

Post filing evidence, e.g. new test data can be used in the prosecution but can't be inserted into the patent specification in view of a ban on introducing new matter. According to the best knowledge of the draftsmen of this report the problem of "predicted versus demonstrated" did not arise in our jurisprudence but we tend to state that, at least in certain predictable technical fields (e.g. new pharmaceutically active compounds) a sound prediction should suffice, while in other more uncertain technical fields (e.g. surprising apparatuses for energy production) demonstration may be required. C. Litigation 9. Is lack of utility or industrial applicability a basis for a validity attack in litigation? [Please just answer 'yes' or 'no'. If 'no', you do not need to answer questions 10-12] 4

10. Is such attack permitted by reason of: both? 11. Is there a material date by which the utility or industrial applicability must be demonstrated? See our answer re point 7 above. 12. What evidence may the patentee adduce in response? For example: (a) can post filing evidence be used; and/or (b) can the patentee rely upon the utility or industrial applicability being soundly predicted as opposed to demonstrated? See our answer re point 8 above. 5